DE60020732D1 - Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung - Google Patents

Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung

Info

Publication number
DE60020732D1
DE60020732D1 DE60020732T DE60020732T DE60020732D1 DE 60020732 D1 DE60020732 D1 DE 60020732D1 DE 60020732 T DE60020732 T DE 60020732T DE 60020732 T DE60020732 T DE 60020732T DE 60020732 D1 DE60020732 D1 DE 60020732D1
Authority
DE
Germany
Prior art keywords
spray drying
fluid bed
nanometer particles
bed spray
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60020732T
Other languages
English (en)
Other versions
DE60020732T2 (de
Inventor
Nicholas J Kerkhof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60020732D1 publication Critical patent/DE60020732D1/de
Publication of DE60020732T2 publication Critical patent/DE60020732T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • General Preparation And Processing Of Foods (AREA)
DE60020732T 1999-12-20 2000-12-19 Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung Expired - Lifetime DE60020732T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17257399P 1999-12-20 1999-12-20
US172573P 1999-12-20
PCT/US2000/034606 WO2001045677A1 (en) 1999-12-20 2000-12-19 Process for producing nanometer particles by fluid bed spray-drying

Publications (2)

Publication Number Publication Date
DE60020732D1 true DE60020732D1 (de) 2005-07-14
DE60020732T2 DE60020732T2 (de) 2006-05-11

Family

ID=22628280

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60020732T Expired - Lifetime DE60020732T2 (de) 1999-12-20 2000-12-19 Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung

Country Status (10)

Country Link
US (1) US7078057B2 (de)
EP (1) EP1239844B1 (de)
JP (3) JP2003518038A (de)
AT (1) ATE297196T1 (de)
AU (2) AU2583401A (de)
CA (1) CA2395129C (de)
DE (1) DE60020732T2 (de)
ES (1) ES2240222T3 (de)
MX (1) MXPA02006079A (de)
WO (2) WO2001045674A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
AU2583401A (en) * 1999-12-20 2001-07-03 Cocensys, Inc. Process for producing nanometer particles by fluid bed spray-drying
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
EP1186347A1 (de) * 2000-09-05 2002-03-13 F. Hoffmann-La Roche Ag Verfahren und Vorrichtung zum Zerstäuben von Flüssigkeiten
US6746635B2 (en) * 2001-08-08 2004-06-08 Brown University Research Foundation Methods for micronization of hydrophobic drugs
EP1435916B1 (de) * 2001-10-10 2006-04-26 Boehringer Ingelheim Pharmaceuticals Inc. Pulververarbeitung mit unter druck stehenden gasförmigen fluids
AU2002365893C1 (en) * 2001-11-30 2009-07-09 Invitrogen Corporation Cell culture media
EP1458365A1 (de) * 2001-12-21 2004-09-22 Celator Technologies Inc. Verbesserte polymer-lipid arzneiverabreichungsträger
US20070059358A1 (en) * 2003-07-02 2007-03-15 Tianjin Tasly Pharmaceutical Co., Ltd., China Matrix adjuvants and the drop pills prepared with them
US7198653B2 (en) 2003-07-31 2007-04-03 Delavau Llc Calcium carbonate granulation
TW200524541A (en) * 2003-11-17 2005-08-01 Cargill Inc Lecithin-containing granular compositions and methods of their preparation
EP1729727B1 (de) * 2004-04-01 2019-07-03 Hadasit Medical Research Services and Development Ltd. Verbesserte formulierungen des 6-mercaptopurins
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
US20070298111A1 (en) * 2004-10-01 2007-12-27 Eisai R&D Management Co., Ltd. Fine Particle-Containing Composition and Manufacturing Method Therefor
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
DK1848430T3 (da) * 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
KR20070119631A (ko) 2005-02-10 2007-12-20 글락소 그룹 리미티드 사전-분류 기술을 이용한 락토오스 제조 공정 및 이로부터제조된 약제 제형
DE102005011786A1 (de) 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
BRPI0611433A2 (pt) * 2005-05-05 2010-09-08 Sanofi Aventis Us Llc formulações estáveis de nanopartìcula
EP1959966B1 (de) * 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Ganaxolon-formulierungen und verfahren zu ihrer herstellung und verwendung
JP2007297348A (ja) * 2006-05-02 2007-11-15 Daito Kk エバスチンを含有する錠剤
JP2007306950A (ja) 2006-05-15 2007-11-29 Osaka Univ 薬効成分ナノ粒子分散液の製造方法
WO2007132852A1 (ja) * 2006-05-15 2007-11-22 Ebara Corporation 難水溶性医薬
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
US9138414B1 (en) 2006-09-15 2015-09-22 Delavau Llc Calcium supplement having enhanced absorption
JP2010510988A (ja) 2006-11-28 2010-04-08 マリナス ファーマシューティカルズ ナノ粒子製剤とその製造方法およびその利用
US20080161594A1 (en) * 2006-12-29 2008-07-03 Industrial Technology Research Institute Method for fabricating nanoparticles containing fenofibrate
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
FR2918277B1 (fr) * 2007-07-06 2012-10-05 Coretecholding Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues
KR100991675B1 (ko) * 2007-08-06 2010-11-04 한국식품연구원 식물 정유를 함유하는 나노에멀션과 나노입자 및 그제조방법
GB0720516D0 (en) * 2007-10-18 2007-11-28 Cadbury Schweppes Plc Comestible products
FI121990B (fi) * 2007-12-20 2011-07-15 Beneq Oy Laite sumun ja hiukkasten tuottamiseksi
US20100055246A1 (en) * 2008-08-28 2010-03-04 Dong June Ahn Nutrition delivery capsules for functional foods
US20100055187A1 (en) * 2008-08-28 2010-03-04 Dong June Ahn Nanovitamin synthesis
GB0815852D0 (en) * 2008-09-01 2008-10-08 Unilever Plc Improvements relating to pharmaceutical compositions
SG171362A1 (en) * 2008-11-20 2011-07-28 Avantor Performance Mat Inc Directly compressible high functionality granular dibasic calcium phosphate based co-processed excipient
KR20110104120A (ko) 2009-01-26 2011-09-21 테바 파마슈티컬 인더스트리즈 리미티드 극미립자를 이용한 담체 코팅 방법
WO2010111132A2 (en) 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9084944B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
WO2012110469A1 (en) 2011-02-17 2012-08-23 F. Hoffmann-La Roche Ag A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
WO2013046045A1 (en) 2011-09-27 2013-04-04 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
US10076496B2 (en) * 2011-11-11 2018-09-18 The Chinese University Of Hong Kong Engineering of polymer-stabilized nanoparticles for drugs with Log P values below 6 by controlled antisolvent precipitation
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
EP2884962B1 (de) * 2012-08-17 2019-05-01 Smartek International LLC Präparat aus entwässerten liposomen zur verwendung in komprimierbaren abgabesystemen
BR112015011515A2 (pt) 2012-11-19 2017-08-22 Dr Reddy´S Laboratories Ltd Composições farmacêuticas de inibidores de cetp
CN104255715A (zh) * 2014-09-01 2015-01-07 李晓枫 一种纳米生物农药组合物及其制备方法
PT3212169T (pt) 2014-10-31 2021-05-06 Bend Res Inc Processo para formar domínios ativos dispersos numa matriz
EP3340982B1 (de) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Verbindungen zur behandlung von immun- und entzündungserkrankungen
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
KR20180082457A (ko) 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
WO2017066619A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
CN108699510A (zh) * 2015-12-30 2018-10-23 生命技术公司 细胞培养用层状颗粒及其制法
MX2018016046A (es) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN108586624A (zh) * 2018-05-15 2018-09-28 郑州轻工业学院 一种空气常压等离子体射流改性微晶淀粉的方法
JP2021535112A (ja) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
EP3866773A4 (de) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Kohlenmonoxid-prodrugs zur behandlung von erkrankungen
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
JP2023503928A (ja) 2019-12-06 2023-02-01 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK125813B (da) 1971-04-16 1973-05-07 Niro Atomizer As Apparat til tørring af fugtige pulvere.
US4511592A (en) 1982-03-11 1985-04-16 Scm Corporation Preparation of acidulated meat emulsions
US4623588A (en) * 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
CA1264566A (en) 1984-09-05 1990-01-23 Tetsuji Iwasaki Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder
US4689297A (en) 1985-03-05 1987-08-25 Miles Laboratories, Inc. Dust free particulate enzyme formulation
DK158532C (da) 1987-07-14 1990-10-29 Niro Atomizer As Toerreapparat, der arbejder med fluid bed, og lejeplade dertil
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5015480A (en) * 1987-11-25 1991-05-14 Eli Lilly And Company Film coating formulations
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US5006204A (en) 1988-08-10 1991-04-09 A/S Niro Atomizer Apparatus for crystallizing whey
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
EP0441092A1 (de) 1990-02-08 1991-08-14 Niro Holding A/S Verfahren und Vorrichtung zur Wärmebehandlung eines körnigen Produktes
DE69014204T2 (de) 1990-09-11 1995-05-18 Niro Holding As Verfahren und Vorrichtung zum Behandeln eines pulverförmigen oder körnigen Materials oder Produkts mit Gas.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
DE69104183T2 (de) 1991-04-05 1995-05-11 Niro Holding As Wirbelbettvorrichtung und Verfahren zu ihrer Herstellung.
WO1993025198A1 (en) * 1992-06-12 1993-12-23 Teijin Limited Ultrafine powder for inhalation and production thereof
US5325606A (en) 1992-12-23 1994-07-05 Niro A/S Process and apparatus for drying and calcining sodium bicarbonate
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
JP2700141B2 (ja) * 1993-09-17 1998-01-19 富士化学工業株式会社 リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤
EP0752860B1 (de) 1994-02-14 2000-08-23 Euro-Celtique S.A. Androstane und pregnane zur allosterischen modulation des gaba-rezeptors
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
JPH0820537A (ja) * 1994-07-06 1996-01-23 Toa Eiyoo Kk 抗潰瘍剤含有固形製剤
NZ292980A (en) 1994-09-29 1999-02-25 Andaris Ltd Smooth, spherical water-soluble microparticles as therapeutic or diagnostic vehicles
ES2155543T3 (es) 1994-11-23 2001-05-16 Cocensys Inc Serie de androstano y pregnano para modulacion alosterica del receptor de gaba.
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5741818A (en) 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
EP0862420A4 (de) * 1995-10-13 1999-11-03 Penn State Res Found Synthese von arzneistoffnanopartikeln durch sprühtrocknung
JP4183279B2 (ja) * 1997-04-15 2008-11-19 アール ピー シェーラー テクノロジーズ インコーポレーテッド 医薬用加水分解セルロース顆粒
JP3293524B2 (ja) * 1997-06-17 2002-06-17 有限会社薬研 イチョウ葉抽出エキス担持粉体複合物及びその製造方法
AU2583401A (en) * 1999-12-20 2001-07-03 Cocensys, Inc. Process for producing nanometer particles by fluid bed spray-drying

Also Published As

Publication number Publication date
EP1239844A1 (de) 2002-09-18
MXPA02006079A (es) 2004-08-23
AU2583401A (en) 2001-07-03
DE60020732T2 (de) 2006-05-11
US20030211162A1 (en) 2003-11-13
US7078057B2 (en) 2006-07-18
JP2010090132A (ja) 2010-04-22
CA2395129A1 (en) 2001-06-28
AU778931B2 (en) 2004-12-23
WO2001045677A1 (en) 2001-06-28
EP1239844B1 (de) 2005-06-08
JP2012102135A (ja) 2012-05-31
WO2001045674A1 (en) 2001-06-28
JP2003518038A (ja) 2003-06-03
AU2281401A (en) 2001-07-03
CA2395129C (en) 2008-12-16
ATE297196T1 (de) 2005-06-15
ES2240222T3 (es) 2005-10-16

Similar Documents

Publication Publication Date Title
DE60020732D1 (de) Verfahren zur herstellung von nanometer partikeln durch fliessbett- sprühtrocknung
DE50001620D1 (de) Verfahren zur herstellung von perlpolymerisaten
DE59007616D1 (de) Verfahren zur Herstellung von kugelförmigen, harten mono- oder oligodispersen Teilchen aus Melaminharz.
ATE344275T1 (de) Verfahren zur herstellung eines agglomerats von n-(n-(3,3-dimethylbutyl)-l- alpha aspartyl)-l- phenylalanine-1-methylester
ATE296791T1 (de) Verfahren zur herstellung von direkt tablettierbarem alpha-mannit
DE69613639D1 (de) Verfahren zur Herstellung eines Agglomerates
ATE513885T1 (de) Agglomeriertes schleifmittelkorn und verfahren zu seiner herstellung
DE69530852D1 (de) Verfahren zur Herstellung eines Reaktionsproduktes bestehend aus einer Neutralisationsstufe von Alkylphenolen und einer Karboxylierungsstufe der hergestellten Alkylphenate
DE69205640T2 (de) Verfahren zur Herstellung eines Mikroelektronisches Bauelement.
DE60030999D1 (de) Verfahren zur herstellung von teilchen
DE60225433D1 (de) Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen
DE69920676D1 (de) Verfahren zur Herstellung von Amin-Umsetzungsprodukt-Teilchen
ATE152476T1 (de) Verfahren zur herstellung von granulaten
ATE141518T1 (de) Echogene partikel, verfahren zu deren herstellung und deren verwendung
ATE238323T1 (de) Pulverisierte-sorbitol und ihr verfahren zur herstellung
DE60204125D1 (de) Verfahren zur herstellung von metoprolol enthaltenden mikropartikeln
DE69828426D1 (de) Verfahren zur herstellung von polymerteilchen
DE69723503D1 (de) Ultrafeines Partikel, Verfahren seiner Herstellung, Herstellung von Formkörper aus diesen Partikeln und Fullerenes und deren Herstellungsverfahren
DE50105968D1 (de) VERFAHREN ZUR HERSTELLUNG VON AlKYLVERBRÜCKTEN LIGANDSYSTEMEN UND ÜBERGANGSMETALLVERBINDUNGEN
DE69836496D1 (de) Verfahren zur herstellung von beta-(1,3)-d-glukan aus pilzen
DE60042777D1 (de) Verfahren für die herstellung von monodispergierten polymerteilchen
DE69501311D1 (de) Verfahren zur Herstellung von Polymerpartikeln
DE69015134T2 (de) Verfahren zur Herstellung von geformten Gegenständen aus sinterfähigem Pulver.
DE60003961D1 (de) Wässriges Verfahren zur Herstellung von linearen Chinacridonen mit reduzierter Teilchengrösse
ATE140013T1 (de) Verfahren zur herstellung von syndiotaktischen copolymeren aus propylen und olefinen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition